National Research (NASDAQ:NRC) Shares Cross Above 200 Day Moving Average – What’s Next?

National Research Corporation (NASDAQ:NRC)’s stock price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $15.23 and traded as high as $18.80. National Research shares last traded at $18.77, with a volume of 44,612 shares traded.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d+)” rating on shares of National Research in a research report on Monday. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, National Research presently has an average rating of “Sell”.

National Research Price Performance

The firm has a fifty day moving average price of $16.38 and a two-hundred day moving average price of $15.25. The company has a quick ratio of 0.53, a current ratio of 0.53 and a debt-to-equity ratio of 5.31. The stock has a market capitalization of $425.33 million, a P/E ratio of 26.81 and a beta of 0.47.

National Research (NASDAQ:NRC) last announced its quarterly earnings results on Monday, October 27th. The company reported $0.23 earnings per share (EPS) for the quarter. The company had revenue of $34.61 million for the quarter. National Research had a net margin of 11.76% and a return on equity of 98.26%.

National Research Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 9th. Stockholders of record on Friday, December 26th will be issued a dividend of $0.16 per share. The ex-dividend date is Friday, December 26th. This is a positive change from National Research’s previous quarterly dividend of $0.12. This represents a $0.64 dividend on an annualized basis and a dividend yield of 3.4%. National Research’s dividend payout ratio is currently 91.43%.

Hedge Funds Weigh In On National Research

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NRC. Los Angeles Capital Management LLC bought a new position in National Research during the 2nd quarter valued at about $403,000. QV Investors Inc. boosted its holdings in shares of National Research by 7.6% during the 2nd quarter. QV Investors Inc. now owns 381,310 shares of the company’s stock valued at $6,406,000 after acquiring an additional 26,950 shares during the last quarter. Vanguard Personalized Indexing Management LLC bought a new stake in shares of National Research in the second quarter worth approximately $444,000. CWM LLC grew its stake in shares of National Research by 192.0% in the second quarter. CWM LLC now owns 6,847 shares of the company’s stock worth $115,000 after acquiring an additional 4,502 shares during the period. Finally, Rhumbline Advisers raised its holdings in shares of National Research by 4.5% during the first quarter. Rhumbline Advisers now owns 22,204 shares of the company’s stock valued at $284,000 after purchasing an additional 946 shares during the last quarter. 47.26% of the stock is owned by institutional investors.

About National Research

National Research Corp (NASDAQ: NRC), also known as NRC Health, is a healthcare analytics and performance improvement company specializing in patient and employee experience measurement. The company’s cloud-based platform enables healthcare providers to collect real-time feedback through patient satisfaction surveys, post-discharge outreach, and employee engagement tools. NRC Health integrates clinical, operational and financial data to deliver actionable insights that support quality improvement initiatives and value-based care programs.

Since its founding in the early 1990s and headquartered in Lincoln, Nebraska, National Research has expanded beyond its regional roots to serve more than 1,600 hospitals and 12,000 care sites across the United States and Canada.